Announcing a new publication for Acta Materia Medica journal. G protein-coupled receptors (GPCRs) are important, potential drug targets for the treatment of metabolic disorders, such as obesity. GPCRs crosstalk with several transducers, including heterotrimeric G proteins, GPCR kinases (GRKs), and β-arrestins.
GPCR-biased agonism has raised the potential of novel drug development to preferentially activate therapeutic signaling pathways over pathways that lead to unwanted side effects. The obesity epidemic and its metabolic complications continue to be a major global public health threat but effective treatments are limited. The accelerated development of structural techniques, like X-ray crystallography and cryo-electron microscopy, has paved the way to understanding how biased agonism measured at GPCRs results in specific downstream physiologic responses.
The authors of this article summarize well-validated GPCR targets and outline several new and promising receptors for obesity treatment. The significance of deciphering the role of GPCRs in obesity pathology and biased signaling for drug development are highlighted.
Source:
Journal reference:
Shen, S., et al. (2024) G protein-coupled receptor-biased signaling: potential drug discovery to facilitate treatment of metabolic diseases. Acta Materia Medica. doi.org/10.15212/AMM-2023-0041.
Researchers discover how mutations disrupt protein splicing and cause disease